Canada's Aurinia Q2 revenue rises on LUPKYNIS sales

Aurinia Pharmaceuticals

06/08/2026 13:11

Overview
Canada biopharma's Q2 diluted EPS for Q2 increased 75% yr/yr
Company repurchased 5 mln shares for $74.9 mln in H1 2026

Outlook
Aurinia reiterates 2026 total revenue guidance of $315 mln to $325 mln
Company expects 2026 net product sales of $305 mln to $315 mln

Result Drivers
LUPKYNIS SALES - Co attributed Q2 revenue growth to higher sales of LUPKYNIS for lupus nephritis
OPERATING EXPENSES - Lower operating expenses contributed to improved profitability in Q2
LICENSE AND ROYALTY REVENUE - Growth in license, collaboration and royalty revenue supported overall revenue increase

Company press release: ID:nBwbL53Jma

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Total Revenue
 
$83.2 mln
 
Q2 Net Income
 
$37.41 mln
 
Q2 Operating Expenses
 
$36.88 mln
 
Q2 Operating Income
 
$46.34 mln
 
Q2 Pretax Profit
 
$48.79 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $17.00, about 11.9% above its August 5 closing price of $15.19
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 17 three months ago

Reuters Recommended Reads
Aug 4 - Travere Therapeutics Q2 product sales rise on FILSPARI demand
Aug 6 - Canada's Knight Therapeutics Q2 revenue beats on growth in promoted portfolio
Aug 6 - Ligand Pharmaceuticals Q2 revenue rises on royalty growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)